Since increasing evidence underlines the prominent role of systemic inflammation in carcinogenesis, the inflammation burden index (IBI) has emerged as a promising biomarker to estimate survival outcomes among cancer patients. The IBI has only been validated in Eastern gastric cancer (GC) patients; therefore, the aim of this study was to evaluate the IBI as a prognostic biomarker in Central European GC patients undergoing multimodal treatment. Ninety-three patients with histologically confirmed GC who underwent multimodal treatment between 2013 and 2021 were included. Patient recruitment started with the standardization of neoadjuvant chemotherapy (NAC). Blood samples were obtained one day prior to surgical treatment. The textbook outcome (TO) served as the measure of surgical quality, and tumor responses to NAC were evaluated according to Becker’s system tumor regression grade (TRG). A high IBI was associated with an increased risk of postoperative complications (OR 2.95, 95% CI 1.13–7.72). In multivariate analysis, a high IBI (HR = 2.56, 95% CI 1.28–5.13) and a high neutrophil-to-lymphocyte ratio (NLR, HR = 2.55, 95% CI 1.32–4.94) were associated with an increased risk of death, while NAC administration (HR = 0.40, 95% CI 0.18–0.90) and TO achievement (HR = 0.42, 95% CI 0.22–0.81) were associated with a lower risk of death. The IBI was associated with postoperative complications and mortality among GC patients undergoing multimodal treatment.
随着越来越多的证据表明全身性炎症在癌症发生中具有重要作用，炎症负荷指数（IBI）已成为评估癌症患者生存结局的一种有前景的生物标志物。目前IBI仅在东亚胃癌患者中得到验证，因此本研究旨在评估其作为中欧地区接受多模式治疗胃癌患者的预后生物标志物的价值。研究纳入了2013年至2021年间经组织学确诊并接受多模式治疗的93例胃癌患者。患者入组始于新辅助化疗（NAC）标准化实施阶段。血液样本采集于手术治疗前一天。以教科书结局（TO）作为手术质量的衡量标准，并根据Becker肿瘤退缩分级系统评估肿瘤对NAC的反应。高IBI值与术后并发症风险增加相关（OR 2.95，95% CI 1.13–7.72）。多变量分析显示，高IBI（HR = 2.56，95% CI 1.28–5.13）和高中性粒细胞与淋巴细胞比值（NLR，HR = 2.55，95% CI 1.32–4.94）与死亡风险增加相关，而接受NAC治疗（HR = 0.40，95% CI 0.18–0.90）和达到TO标准（HR = 0.42，95% CI 0.22–0.81）则与死亡风险降低相关。研究表明，在接受多模式治疗的胃癌患者中，IBI与术后并发症及死亡率存在显著关联。
肿瘤(癌症)患者之家